Stage IV Non-Small Cell Lung Cancer without Driver Alterations
Key Points
Key Points
This clinical practice guideline update addresses two overarching clinical questions:
- What are the most effective first-line treatment options for patients with stage IV NSCLC without driver alterations, based on cancer subtype?
- What are the most effective second-line and subsequent treatment options for patients with stage IV NSCLC without driver alterations based on cancer subtype?
Treatment
...reatmen...
NOTE: For recommendations with mu...
...stion 1: What are the most effective first-line...
...-Squamous Cell Carcinoma (Non-SCC...
...s with programmed death-ligand 1 or...
...nts with a programmed death-ligand 1 or programm...
...nts with a programmed death-ligand 1 or programm...
1.3. For patients with a programmed death-ligand...
....4. For patients with a programmed death-l...
...tients with a programmed death-ligand 1 or...
...or patients with a programmed death-ligand 1 or...
...PD-L1 expression TPS, 1–49%:...
...For patients with PD-L1 expression TPS, 1–49%,...
...8. For patients with PD-L1 expressi...
.... For patients with PD-L1 expression TPS, 1–4...
...nts with PD-L1 expression TPS, 1–49%, clin...
...For patients with PD-L1 expression TPS, 1–49...
...ients who are ineligible for or de...
...unknown or negative PD-L1 expressi...
...patients with unknown or negative PD-L1 expressi...
...ents with unknown or negative PD-L1 expression,...
...atients with unknown or negative PD-L1 expr...
.... For patients with unknown or negative P...
...7. For patients with unknown or negative PD...
...Cell Carcinoma (SCC)...
...with PD-L1 expression, TPS ≥50%:...
...atients with PD-L1 expression, TPS ≥50%,...
...ts with PD-L1 expression, TPS ≥50%, clinic...
...atients with PD-L1 expression, TPS â‰...
...ts with PD-L1 expression, TPS ≥50%, clinician...
...5. For patients with PD-L1 expression,...
...ts with PD-L1 expression TPS, 1–49%:
...For patients with PD-L1 expression TPS, 1â...
...ients with PD-L1 expression TPS, 1–49...
3.8. For patients with PD-L1 expression TPS, 1–...
...ents with PD-L1 expression TPS, 1–49%, cli...
...atients with PD-L1 expression TPS,...
...with unknown or negative PD-L1 expres...
...ients with unknown or negative PD-L1 expre...
...atients with unknown or negative PD-L1 e...
.... For patients with unknown or negative PD-L1...
...For patients with unknown or negati...
...s with Unspecified Histology...
...or patients with unknown or negati...
...For patients with unknown or negative PD-L1 e...
...For patients with unknown or negative PD-L1 expr...
...Bevacizumab should be avoided for patients with s...
...ients with contraindications to beva...
...atients with Unspecified His...
....8. Bevacizumab should be avoided for...
...e bevacizumab given with pemetrexed has...
Clinical Question 2: What are the most effective...
Patients previously treated with immune checkpoi...
...or patients previously treated with...
...reviously treated with chemotherapy and immune ch...
...tients previously treated with chemotherapy and i...
...n patients previously treated with che...
...igure 1. Second-Line and Subsequent Tre...
...First-Line Treatment Options for Pati...
...ure 3. First-Line Treatment Options for Patients W...